Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00107029
Status:
COMPLETED
Last Update Posted:
2017-02-28
First Post:
2005-04-04
Brief Title:
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV Youth
Sponsor:
University of North Carolina Chapel Hill
Organization:
University of North Carolina Chapel Hill
Study Overview
Official Title:
Evaluation of HIV-Specific CD8 T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This protocol is a study of HIV young people who were identified as having certain HIV-1 specific T-cell responses and genetic markers while previously enrolled in the 5-year longitudinal adolescent study REACH Blood samples will be collected a medical and medication history and physical examination will be performed every 6 months for a total of 2 years
Detailed Description:
Numerous studies have demonstrated an association between HLA class I genotypes with differing progression to AIDS in individuals who are followed after being off antiretroviral therapy These studies do not always associate the same HLA class I alleles with the risks of HIV-1 disease progression however they consistently demonstrated that HLA-B35 and B53 portend a bad outcome compared to the better outcome observed in HLA-B27 and B57 carriers Despite this information very little data exists to explain the mechanism of this association
This longitudinal study will look at the HIV-1 specific CD8 T-cell responses and the dominant HIV-1 genotype among individuals identified as HLA-B27 B35 B53 and B57 positive through studies done in collaboration with the REACH project
This longitudinal study will look at the HIV-1 specific CD8 T-cell responses and the dominant HIV-1 genotype among individuals identified as HLA-B27 B35 B53 and B57 positive through studies done in collaboration with the REACH project
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None